Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RO7300490 |
Synonyms | |
Therapy Description |
RO7300490 is a bispecific antibody that targets CD40 and FAP, which may activate CD40 at tumor stromal and lead to antitumor activity (PMID: 34043482, PMID: 33771854). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RO7300490 | RO-7300490|RO 7300490|FAP-CD40 | CD40 Antibody 14 | RO7300490 is a bispecific antibody that targets CD40 and FAP, which may activate CD40 at tumor stromal and lead to antitumor activity (PMID: 34043482, PMID: 33771854). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04857138 | Phase I | RO7300490 Atezolizumab + RO7300490 | A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors | Completed | GBR | FRA | ESP | DNK | 1 |